Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain

Journal of Clinical Investigation

Volumn 100, Issue 2, 1997, Pages 390-397

  Gressens, Pierre ^a   Marret, Stéphane ^b   Hill, Joanna M ^c   Brenneman, Douglas E ^c   Gozes, Illana ^d   Fridkin, Mati ^e   Evrard, Philippe ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

^e WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Activity dependent neurotrophic factor; Cerebral palsy; Ibotenic acid; N methyl D aspartate; Vasoactive intestinal peptide

Indexed keywords

IBOTENIC ACID; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CYST; BRAIN DEVELOPMENT; BRAIN INJURY; BRAIN NECROSIS; CEREBRAL PALSY; CYTOTOXICITY; MICROGYRIA; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL;

EID: 0030751248     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119545     Document Type: Article

References (61)

1. Hagberg, B., G. Hagberg, I. Olow, and L. v. Wendt. 1996. The changing panorama of cerebral palsy in Sweden. VII. Prevalence and origin in the birth year period 1987-90. Acta Paediatr. 85:954-960.
2. Pharoah, P., T. Cooke, R.W. Cooke, and L. Rosenbloom. 1990. Birth-weight specific trends in cerebral palsy. Arch. Dis. Child. 65:602-606.
3. Nelson, K.B., and J.H. Ellenberg. 1986. Antecedents of cerebral palsy. Multivariate analysis of risk. N. Engl. J. Med. 315:81-86.
4. Evrard, P., N. Miladi, C. Bonnier, and P. Gressens. 1992. Normal and abnormal development of the brain. In Child Neuropsychology, I. Rapin and S.J. Segalowitz, editors. Handbook of Neuropsychology. Elsevier Science B.V., Amsterdam. 11-44.
5. Evrard, P., S. Marret, and P. Gressens. 1995. Environmental determinants of brain development, with a special emphasis on the excitotoxic cascade at the consecutive developmental steps. In Aktuelle Neuropädiatrie. D. Rating, editor. Ciba-Geigy Verlag, Wehr, Germany. 22-33.
6. Volpe, J.J. 1995. Neurology of the Newborn. W.B. Saunders Co., Philadelphia. 876 pp.
7. Murphy, D.J., S. Sellers, I.Z. MacKenzie, P.L. Yudkin, and A.M. Johnson. 1995. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet. 346:1449-1454.
8. Zupan, V., P. Gonzalez, T. Lacaze-Masmonteil, C. Boithias, A.M. d'Allest, M. Dehan, and J.C. Gabilan. 1996. Periventricular leukomalacia: risk factors revisited. Dev. Med. Child Neurol. 38:1061-1067.
9. McDonald, J.W., and M.V. Johnston. 1990. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res. Rev. 15:41-70.
10. Marret, S., R. Mukendi, J.F. Gadisseux, P. Gressens, and P. Evrard. 1995. Effect of ibotenate on brain development: an excitotoxic mouse model of microgyria and posthypoxic-like lesions. J. Neuropathol. Exp. Neurol. 54:358-370.
11. Evrard, P., M.C. Belpaire, G. Boog, N. Elkhazen, J.F. Gadisseux, B. Le Marec, J.P. Misson, J.J. Santini, and M. Van Lierde. 1985. Diagnostic anténatal des affections du SNC: résultats préliminaires d'une étude multicentrique européenne. J. Français d'Echographie. 2:123-126.
12. Barkovich, A.J., P. Gressens, and P. Evrard. 1992. Formation, maturation, and disorders of brain neocortex. Am. J. Neuroradiol. 13:423-446.
13. Barmada, M.A., J. Moossy, and R.M. Shuman. 1979. Cerebral infarcts with arterial occlusion in neonates. Ann. Neurol. 6:495-502.
14. Volpe, J.J. 1992. Perinatal hypoxic-ischemic brain injury: an overview. In Fetal and Perinatal Neurology. Y. Fukuyama, Y. Suzuki, S. Kamoshita, and P. Casaer, editors. Karger, Basel, Switzerland. 232-252.
15. de Vries, L.S., J.S. Wigglesworth, R. Regev, and L.M.S. Dubowitz. 1988. Evolution of periventricular leukomalacia during the neonatal period and infancy. Early Hum. Dev. 17:205-219.
16. Hope, P.L., S.J. Gould, S. Howard, P.A. Hamilton, A.M. De L. Costello, and E.O.R. Reynolds. 1988. Precision of ultrasound diagnosis of pathologically verified lesions in brains of very preterm infants. Dev. Med. Child Neurol. 30: 457-471.
17. Marret, S., P. Gressens, J.F. Gadisseux, and P. Evrard. 1995. Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model for clinical intervention. Dev. Med. Child Neurol. 37:473-484.
18. Brenneman, D.E., T. Nicol, D. Warren, and L.M. Bowers. 1990. Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J. Neurosci. Res. 25:386-394.
19. Brenneman, D.E., L.E. Eiden, and R.E. Siegel. 1985. Neurotrophic action of VIP on spinal cord cultures. Peptides. 6 (Suppl.):35-39.
20. Brenneman, D.E., and L.E. Eiden. 1986. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc. Natl. Acad. Sci. USA. 83:1159-1162.
21. Pincus, D.W., E.M. DiCicco-Bloom, and I.B. Black. 1990. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature (Lond.). 343:564-567.
22. Gressens, P., J.M. Hill, I. Gozes, M. Fridkin, and D.E. Brenneman. 1993. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature (Lond.). 362:155-158.
23. Gressens, P., J.M. Hill, B. Paindaveine, I, Gozes, M. Fridkin, and D.E. Brenneman. 1994. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J. Clin. Invest. 94:2020-2027.
24. Brenneman, D.E., and I. Gozes. 1996. A fentomolar-acting neuroprotective peptide. J. Clin. Invest. 97:2296-2307.
25. Brenneman, D.E., J.M. Hill, G.W. Glazner, I. Gozes, and T.M. Phillips. 1995. Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival. Int. J. Dev. Neurosci. 13:187-200.
26. Festoff, B.E., P.G. Nelson, and D.E. Brenneman. 1996. Prevention of activity-dependent neuronal death: vasoactive intestinal polypeptide stimulates astrocytes to secrete the thrombin-inhibiting, neurotrophic serpin, protease nexin. J. Neurobiol. 30:255-266.
27. Arimura, A. 1992. Receptors for pituitary adenylate cyclase-activating polypeptide. Comparison with vasoactive intestinal peptide receptors. Trends Endocrinol. Metab. 3:288-294.
28. Magistretti, P.J., and M. Schorderet. 1984. VIP and noradrenaline act synergistically to increase cyclic AMP in cerebral cortex. Nature (Lond.). 308: 280-282.
29. Gozes, I., S.K. McCune, L. Jacobson, D. Warren, T.W. Moody, M. Fridkin, and D.E. Brenneman. 1991. An antagonist to vasoactive intestinal peptide: effects on cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 257:959-966.
30. Martin, J.L., D. Gasser, and P.J. Magistretti. 1995. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide potentiate c-fos expression induced by glutamate in cultured cortical neurons. J. Neurochem. 65: 1-9.
31. Said, S.I., H.I. Berisha, and H. Pakbaz. 1996. Excitotoxicity in the lung: N-methyl-D-aspartate-induced nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase. Proc. Natl. Acad. Sci. USA. 93:4688-4692.
32. Gozes, I., E. Meltzer, S. Rubinraut, and D.E. Brenneman, 1989. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by a novel antagonist. Endocrinology. 125:2945-2949.
33. Gozes, Y., D.E. Brenneman, M. Fridkin, R. Asofsky, and I. Gozes. 1991. A VIP antagonist distinguishes VIP receptors in spinal cord and lymphocytes. Brain Res. 540:319-321.
34. Hill, J.M., R.F. Mervis, J. Politi, S.K. McCune, I. Gozes, M. Fridkin, and D.E. Brenneman. 1994. Blockade of VIP during neonatal development induces neuronal damages and increases VIP and VIP receptors in brain. Ann. NY. Acad. Sci. 739:211-225.
35. Hill, J.M., I. Gozes, J.L. Hill, M. Fridkin, and D.E. Brenneman. 1991. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides USA. 12:187-192.
36. Gozes, I., G. Lilling, R. Glazer, A. Ticher, I.E. Ashkenazi, A. Davidson, S. Rubinraut, M. Fridkin, and D.E. Brenneman. 1995, Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273:161-167.
37. Gozes, I., A. Bardea, A. Reshef, R. Zamostiano, S. Zhukovsky, S. Rubinraut, M. Fridkin, and D.E. Brenneman. 1996. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc. Natl. Acad. Sci. USA 93:427-432.
38. Gozes, I., A. Reshef, D. Salah, S. Rubinraut, and M. Fridkin. 1994. Stearyl-norleucine-VIP, a novel VIP analogue for noninvasive impotence treatment. Endocrinology. 134:2121-2125.
39. Hill, J.M., A. Harris, and D.I. Hilton-Clarke. 1992. Regional distribution of guanine nucleotide-sensitive and guanine nucleotide-insensitive vasoactive intestinal peptide receptors in rat brain. Neuroscience. 48:925-932.
40. Ishiara, T., R. Shigemoto, K. Mori, K. Takahashi, and S. Nagata. 1992. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal peptide. Neuron. 8:811-819.
41. Sreedharan, S.P., D.R. Patel, J.X. Huang, and E.J. Goetzl. 1993. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem. Biophys. Res. Commun. 193:546-553.
42. Lutz, E.M., W.J. Sheward, K.M. West, J.A. Morrow, G. Fink, and A.J. Harmar. 1993. The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS (Fed. Eur. Biochem. Soc.) Lett. 334:3-8.
43. Adamaou, J.E., N. Aiyar, S. Van Horn, and N.A. Elshourbagy. 1995. Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. Biochem. Biophys. Res. Commun. 209:385-392.
44. Spengler, D., C. Waeber, C. Pantaloni, F. Hoelboer, J. Bockaert, P.H. Seeburg, and L. Journot. 1993. Differential signal transduction by five splice variants of the PACAP receptor. Nature (Lond.). 365:170-175.
45. Gressens, P., B. Paindaveine, J.M. Hill, D.E. Brenneman, and P. Evrard. 1997. Growth factor properties of VIP during early brain development: whole embryo culture and in vivo studies. Ann. NY Acad. Sci. 814:152-160.
46. Fatatis, A., L.A. Holtzclaw, R. Avidor, D.E. Brenneman, and J.T. Russel. 1994. Vasoactive intestinal peptide increases intracellular calcium in astroglia: synergism with alpha-adrenergic receptors. Proc. Natl. Acad. Sci. USA 91: 2036-2040.
47. Arimura, A., A. Somogyvari-Vigh, C. Well, R.C. Fiore, I. Tatsuno, V. Bay, and D.E. Brenneman. 1994. PACAP functions as a neurotrophic factor. Ann. NY Acad. Sci. 739:228-243.
48. Olah, Z., C. Lehel, W.B. Anderson, D.E. Brenneman, and D.V. Agoston. 1994. Subnanomolar concentration of VIP induces the nuclear translocation of proteine kinase C in neonatal rat cortical astrocytes. J. Neurosci. Res. 39: 355-363.
49. Unterman, T.G., T.A. Buchanan, and N. Freinkel. 1989. Access to maternal insulin to the rat conceptus prior to allantoic placentation. Diabetes Res. Clin. Pract. 10:115-120.
50. Obregon, M.J., J. Mallol, R. Pastor, and G. Morreale de Escobar. 1984. L-thyroxine and 3,3′,5′-triiodo-L-thyroxine in rat embryos before onset of fetal thyroid function. Endocrinology. 114:305-307.
51. Page, E.W., C.A. Villee, and D.B. Villee. 1981. Human reproduction. In Essentials of Reproductive and Perinatal Medicine. 3rd edition. W.B. Saunders Co., Philadelphia. 526 pp.
52. Medlock, E.S., D.L. Kaplan, M. Cecchini, T.R. Ulich, J. del Castillo, and J. Andresen. 1993. Granulocyte-macrophage colony stimulating factor crosses the placenta and stimulates fetal rat granulopoiesis. Blood. 81:916-922.
53. Letterio, J.J., A.G. Geiser, A.B. Kulkarni, N.S. Roche, M.B. Sporn, and A.B. Roberts. 1994. Maternal rescue of transforming growth factor-beta1 null mice. Science (Wash. DC). 264:1936-1938.
54. Hill, J.M., S.K. McCune, R.J. Alvero, G.W. Glazner, K.A. Henins, S.F. Stanziale, J.R. Keimowitz, and D.E. Brenneman. 1996. Maternal vasoactive intestinal peptide and the regulation of embryonic growth in rodents. J. Clin. Invest. 97:202-208.
55. Ottesen, B., H. Ulrichsen, J. Fahrenkrug, J.J. Larsen, G. Wagner, L. Schierup, and F. Sondergaard. 1982. Vasoactive intestinal polypeptide and the female genital tract: relationship to reproductive phase and delivery. Am. J. Obstet. Gynecol. 143:414-420.
56. Hayashi, M. 1991. Ontogeny of some neuropeptides in the primate brain. Prog. Neurobiol. (Oxford). 38:231-260.
57. Hill, J.M., D.V. Agoston, P. Gressens, and S.K. McCune. 1994. Distribution of VIP mRNA and two distinct VIP binding sites in the developing rat brain: relation to ontogenic events. J. Comp. Neurol. 342:186-205.
58. Waschek, J.A., J. Ellison, D.T. Bravo, and V. Handley. 1996. Embryonic expression of vasoactive intestinal peptide (VIP) and VIP receptor genes. J. Neurochem. 66:1762-1765.
59. Thordstein, M., R. Bagenholm, K. Thiringer, and I. Kjellmer. 1993. Scavengers of free oxygen radicals in combination with magnesium ameliorate perinatal hypoxic-ischemic brain damage in the rat. Pediatr. Res. 34:23-26.
60. Holtzman, D.M., R.A. Sheldon, W. Jaffe, Y. Cheng, and D.M. Ferriero. 1996. Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury. Ann. Neurol. 39:114-122.
61. Johnston, B.M., E.C. Mallard, C.E. Williams, and P.D. Gluckman. 1996. Insulin-like growth factor-1 is a potent neuronal rescue agent after hypoxic-ischemic injury in fetal lambs. J. Clin. Invest. 97:300-308.